Drugs / BioThrax
BioThrax
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT03518125 | May 2018 → Jan 2019 | anthrax infection | Biomedical Advanced Research and Development Authority | Completed | No outcome recorded |
| Phase 2 | NCT01753115 | Dec 2012 → Aug 2013 | anthrax infection | Emergent BioSolutions | Completed | No outcome recorded |
| Phase 2 | NCT00133484 | ? → May 2007 | anthrax infection | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01491607 | Nov 2011 → May 2012 | anthrax infection | Emergent BioSolutions | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT02339155 | Feb 2015 → Jan 2017 | bacterial infectious disease | Emergent BioSolutions | Completed | No outcome recorded |
| Phase 4 | NCT01641991 | Jul 2012 → Mar 2013 | anthrax infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT00119067 | May 2002 → Feb 2010 | — | Centers for Disease Control and Prevention | Completed | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04148118 Comparator | Jan 2020 → Sep 2021 | anthrax infection | BlueWillow Biologics | Completed | No outcome recorded |
| Phase 1 | NCT03352466 Comparator | Jan 2018 → May 2019 | — | Altimmune, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01263691 Comparator | Dec 2010 → May 2012 | anthrax infection | Emergent BioSolutions | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01770743 Comparator | Jan 2013 → Feb 2014 | anthrax infection | Emergent BioSolutions | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03877926 Comparator | Mar 2019 → Aug 2020 | anthrax infection | Emergent BioSolutions | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BioThrax | “Protective antigen (PA)-specific antibody and cell-mediated immune (CMI) responses to annual and alternate booster schedules of Anthrax Vaccine Adsorbed (AVA; BioThrax) were...” PMID 26865594 ↗ Apr 2016 |
| Known as | Anthrax Vaccine Adsorbed | “BioThrax vaccine (Anthrax Vaccine Adsorbed; AVA) is licensed for post-exposure prophylaxis of anthrax disease.” NCT03877926 ↗3“Anthrax Vaccine Adsorbed (AVA or BioThraxTM), the currently available vaccine.” NCT00133484 ↗ “Anthrax Vaccine Adsorbed (AVA), for anthrax prophylaxis” PMID 32333847 ↗ Apr 2020 |
| Known as | AVA | “Protective antigen (PA)-specific antibody and cell-mediated immune (CMI) responses to annual and alternate booster schedules of Anthrax Vaccine Adsorbed (AVA; BioThrax) were...” PMID 26865594 ↗ Apr 20163“BioThrax vaccine (Anthrax Vaccine Adsorbed; AVA) is licensed for post-exposure prophylaxis of anthrax disease.” NCT03877926 ↗ “Anthrax vaccine absorbed made from Bacillus anthracis (AVA)” NCT00133484 ↗ |
| Known as | BioThraxTM | “Anthrax Vaccine Adsorbed (AVA or BioThraxTM), the currently available vaccine.” NCT00133484 ↗ |
| Modality | Vaccine | “Anthrax vaccine (AVA or BioThrax, BioPort Corp. Lansing MI)” NCT00119067 ↗ |
| Route | Intramuscular | “BioThrax administered by the IM route” NCT00119067 ↗ |